The Screening, Diagnostic, Therapy Selection, Recurrence Monitoring and Screening Market Potential are all explored in this report. What is the impact of the COVID pandemic on the Liquid Biopsy market? This report provides a detailed analysis.
Circulating Tumor Cells? Cell-Free DNA? Exosomes? Find out about the technology in readily understood terms that explain the jargon. Find the opportunities and pitfalls. Understand growth expectations and the ultimate potential market size.
A revolution in cancer diagnostics is occurring using in vitro blood testing to identify cancer DNA. The technology has created the possibility of widespread screening for all types of cancers with a blood test.
GRAIL, a new company with impressive backing, has announced a single blood test to detect all cancers. The company is now working on a 10,000-plus subject study, called the Circulating Cell-Free Genome Atlas (CCGA) to help identify cancer early. The technology is moving faster than the market.
New technology that definitively identifies disease conditions from blood samples is poised to replace expensive invasive surgical biopsy procedures. The market is still in its infancy but has just moved out of the development phase and into the growth phase.
The impact on the health care industry is enormous. The report forecasts the market size out to 2024. In addition, the report looks at potential market sizes by country, by cancer and by the four types of usage: screening, diagnosis, therapy selection and recurrence monitoring.
Liquid Biopsy Recent Developments
Liquid Biopsy NGS Panels - Diverse Test Claims
CMS Colon Cancer Screening Memo Bodes Well for Assays
Natera Liquid Biopsy Test Coverage to Expand
Freenome Closes Financing to Support Early Cancer Detection Trial
C$2.6M Liquid Biopsy Initiative
NeoGenomics, Inivata Partner for Lung Cancer Liquid Biopsy
Liquid Biopsy Shows Promise as Screen for Cancers
Inivata launches RaDaRT for the detection of residual disease and recurrence
Liquid Biopsy Assay Detects 50+ Types of Cancer
Liquid Biopsy Study Confirms Concordance with Tissue Biopsy
Guardant Health Liquid Biopsy Expands Medicare Coverage
Aethlon Medical Lands Grant for Exosome Isolation Device
Biolidics to Develop Liquid Biopsy Breast Cancer Test
Liquid Biopsy Equal to Tissue to Indicate Immunotherapy Response
Exact Sciences buys Genomic Health
Multi-Gene Liquid Biopsy Breast Cancer Panel
Bio-Techne receives FDA breakthrough device for prostate cancer liquid biopsy
Thrive to Develop Earlier Detection of Multiple Cancer Types
Guardant Health Liquid Biopsy Test to be Covered by EviCore
Liquid biopsy combines Illumina's 'ultradeep' sequencing with Grail's machine learning
Biocept Partnership Offering for Liquid Biopsy Adds Several Key Services
Natera Commercializes Tumor Whole Exome Sequencing from Plasma
CMC Metals Ltd. (CMCXF:OTCQB) ("CMC" or the "Company") announces that as a result of a review by the British Columbia Securities Commission ("BCSC"), the Company is issuing the following news to clarify previous...
The Board of Trustees of First Trust Energy Infrastructure Fund (the "Fund") , CUSIP 33738C103, previously approved a managed distribution policy for the Fund (the "Managed Distribution Plan") in reliance on exemptive relief received from the...
FGI Industries Ltd. ("FGI" or the "Company"), a leading global supplier of kitchen and bath products, today announced that it will issue financial results for the first quarter 2024 after the market close on Wednesday, May 8, 2024. Management will...
WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of common stock of QuidelOrtho Corporation between February 18, 2022 and April 1, 2024, both dates inclusive (the "Class Period") of the important June 11, 2024 lead...
University of Phoenix College of Nursing is pleased to highlight the recent publication by alumna Gloria Littlemouse, Ph.D. in Nursing, MSN, RN, WCSI Scholar, whose dissertation study informed an article, "Lived Experiences of ICU Nurses During...
Faruqi & Faruqi, LLP, a leading national securities law firm, is investigating potential claims against QuidelOrtho Corporation ("QuidelOrtho" or the "Company") and reminds investors of the June 11, 2024 deadline to seek the role of lead plaintiff...